Brand & Manufacturer VerifiedUnited States
IDEXX Laboratories, Inc.
IDEXX
IDEXX Laboratories is the undisputed global leader in veterinary diagnostics, operating a fundamentally different business model from traditional animal pharmaceutical manufacturers. Founded in 1983 and headquartered in Westbrook, Maine, USA, IDEXX generated USD 4.304 billion in 2025 revenue (up 10.42%), employing 11,000 employees. IDEXX has constructed an unparalleled "razor-and-blade" ecosystem: by placing proprietary diagnostic instruments (Catalyst, ProCyte Dx, SediVue, inVue Dx) in veterinary clinics worldwide, it generates recurring, high-margin consumable reagent and reference laboratory revenue streams with gross margins exceeding 60%.
Strengths:
• Monopolistic Diagnostic Ecosystem: Over 1,900 inVue Dx analyzers installed in 2025 alone, each generating ongoing reagent and reference lab revenue; clinic switching costs are prohibitively high
• Extraordinary Profitability: 60.3% gross margin and $13.6B operating profit in 2025—profit metrics unmatched by any traditional animal pharma company
• Global Reference Lab Network: 80+ commercial reference laboratories across 175+ countries process millions of veterinary samples annually, creating an immense clinical data moat
• Recurring Revenue Model: CAG Diagnostic recurring revenue provides highly predictable income streams insulated from individual product lifecycle risks
• Innovation Track Record: SNAP test platform and ProCyte Dx hematology analyzer are industry gold standards; inVue Dx represents the first AI-driven, slide-free cellular morphology system
Weaknesses:
• Veterinary Visit Dependency: Revenue is directly correlated with clinic visit frequency; any sustained decline in pet owner veterinary spending immediately impacts consumable sales
• Premium Pricing Barrier: High instrument and consumable costs limit penetration in emerging markets and price-sensitive independent practices
• Narrow Therapeutic Scope: Unlike diversified animal health companies, IDEXX has zero presence in pharmaceuticals, vaccines, or nutritional products—a single-industry concentration riskRead More ▼Show Less ▲
Strengths:
• Monopolistic Diagnostic Ecosystem: Over 1,900 inVue Dx analyzers installed in 2025 alone, each generating ongoing reagent and reference lab revenue; clinic switching costs are prohibitively high
• Extraordinary Profitability: 60.3% gross margin and $13.6B operating profit in 2025—profit metrics unmatched by any traditional animal pharma company
• Global Reference Lab Network: 80+ commercial reference laboratories across 175+ countries process millions of veterinary samples annually, creating an immense clinical data moat
• Recurring Revenue Model: CAG Diagnostic recurring revenue provides highly predictable income streams insulated from individual product lifecycle risks
• Innovation Track Record: SNAP test platform and ProCyte Dx hematology analyzer are industry gold standards; inVue Dx represents the first AI-driven, slide-free cellular morphology system
Weaknesses:
• Veterinary Visit Dependency: Revenue is directly correlated with clinic visit frequency; any sustained decline in pet owner veterinary spending immediately impacts consumable sales
• Premium Pricing Barrier: High instrument and consumable costs limit penetration in emerging markets and price-sensitive independent practices
• Narrow Therapeutic Scope: Unlike diversified animal health companies, IDEXX has zero presence in pharmaceuticals, vaccines, or nutritional products—a single-industry concentration risk
United StatesFounded 198311,000USD$4.3 BManufacturing in Maine and… / 100
Listed onNASDAQIDXX
Listed market data
IDXX · NASDAQ · weeklyHistory →- Market cap
- $44.2 B
- Share price
- USD 560.36
- 1Y change
- -11.8%
- Recent change
- -1.1%
- Since first close
- ×618
- Revenue (TTM)
- $4.5 B
10-22 → 10-23
from 1991-06
Revenue FY 2026 · updated 2026-10-23Source ↗
Financial history
Full market historyMonthCloseMarket capChange
- 2026-10USD 560.36$44.2 B+7.3%
- 2026-09USD 522.19$41.2 B-6.2%
- 2026-08USD 556.69$43.9 B-0.4%
- 2026-07USD 559.07$44.1 B+6.2%
- 2026-06USD 526.44$41.5 B-6.6%
- 2026-05USD 563.53$44.4 B+0.5%
- 2026-04USD 560.80$44.2 B-0.2%
- 2026-03USD 561.89$44.3 B-14.4%
- 2026-02USD 656.73$51.8 B-2.0%
- 2026-01USD 670.46$52.9 B-0.9%
- 2025-12USD 676.53$53.4 B-10.1%
- 2025-11USD 752.88$59.4 B—
Monthly closes · 2025-11 – 2026-10 · Full market history
In the press
All coverage →5 latest headlines21- Goldman Sachs starts coverage for IDEXX Laboratories stock at USD 740.00 - ad-hoc-news.dewww.ad-hoc-news.de2026-10-20
- Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report? - Yahoo Financefinance.yahoo.com2026-10-20
- Jefferies downgrades Zoetis, Elanco on pricing risk; prefers IDEXX - Investing.comwww.investing.com2026-10-20
- Jefferies Adjusts Price Target on IDEXX Laboratories to $705 From $795 - marketscreener.comwww.marketscreener.com2026-10-20
- Is IDEXX Laboratories (IDXX) Undervalued On Its Zacks Rank Upgrade? - Simply Wall Streetsimplywall.st2026-10-20
Headlines aggregated from public feeds. Sentiment tags are keyword-based, not editorial judgement.
IDEXX Laboratories is fundamentally distinct from traditional pharmaceutical manufacturers—it is a vertically integrated veterinary diagnostics and health IT powerhouse. IDEXX designs, manufactures, and services a comprehensive ecosystem of point-of-care diagnostic instruments (Catalyst chemistry analyzers, ProCyte Dx hematology analyzers, SediVue urinalysis), rapid assay test kits SNAP tests, and proprietary reagents, all produced in its own ISO-certified manufacturing facilities in Maine and Georgia. The company recently completed a $35 million expansion of its Westbrook World Campus, consolidating advanced R&D and manufacturing.
Beyond hardware, IDEXX operates over 80 commercial reference laboratories worldwide, processing millions of veterinary samples annually. This "razor-and-blade" model—placing instruments in clinics that generate recurring reagent and reference lab revenue streams—yields gross margins exceeding 60%. IDEXX also tightly integrates its VetConnect PLUS software ecosystem, creating high switching costs through proprietary clinical data workflows.
Beyond hardware, IDEXX operates over 80 commercial reference laboratories worldwide, processing millions of veterinary samples annually. This "razor-and-blade" model—placing instruments in clinics that generate recurring reagent and reference lab revenue streams—yields gross margins exceeding 60%. IDEXX also tightly integrates its VetConnect PLUS software ecosystem, creating high switching costs through proprietary clinical data workflows.
Veterinary Diagnostics — Core Business
• Point-of-Care Analyzers: Catalyst / ProCyte Dx / SediVue / inVue Dx
• Rapid Test Kits: SNAP 4Dx Plus / SNAP Feline Triple
• Reference Laboratory Services: 80+ labs globally
• Practice Management Software & Digital Imaging
• Water quality and livestock diagnostics
• Point-of-Care Analyzers: Catalyst / ProCyte Dx / SediVue / inVue Dx
• Rapid Test Kits: SNAP 4Dx Plus / SNAP Feline Triple
• Reference Laboratory Services: 80+ labs globally
• Practice Management Software & Digital Imaging
• Water quality and livestock diagnostics
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $4.3 B | $1.1 B |
| 2024 | $3.9 B | $888 M |
| 2023 | $3.7 B | $845 M |
| 2022 | $3.4 B | $679 M |
| 2021 | $3.2 B | $745 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Westbrook, Maine, United States
Founded
1983
Employees
11,000
Revenue
USD$4.3 B (2025)
Market cap
$44.2 B
Factories
Manufacturing in Maine (Westbrook, Scarborough) and Georgia (Roswell); 80+ reference laboratories globally
Listing
NASDAQ: IDXX
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck Animal Health· $360 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NASDAQ: IDXX , IDEXX Official Website
SEC EDGAR — IDEXX Filings
Wikipedia — IDEXX Laboratories